Briumvi, a New MS Treatment, Could Improve Life Quality
The multiple sclerosis treatment arsenal has gained a new weapon. Shortly after Christmas, the U.S. Food and Drug Administration approved Briumvi (ublituximab), joining a small group of disease-modifying therapies that aim to halt MS progression by knocking out certain B-cells in the immune system. Why does Briumvi target B-cells? B-cells remember past threats to the immune system so that invaders, like viruses, can be stopped quickly. But some B-cells, carrying…Continue Reading